<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM">
      <PMID Version="1">35305254</PMID>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>20</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Print">2193-8245</ISSN>
          <JournalIssue CitedMedium="Print">
            <Volume>11</Volume>
            <Issue>3</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Jun</Month>
            </PubDate>
          </JournalIssue>
          <Title>Ophthalmology and therapy</Title>
          <ISOAbbreviation>Ophthalmol Ther</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Long-Term Safety and Effectiveness of Adalimumab in Japanese Patients with Noninfectious Intermediate, Posterior, or Panuveitis: Post-Marketing Surveillance of 251 Patients.</ArticleTitle>
        <Pagination>
          <StartPage>1147</StartPage>
          <EndPage>1161</EndPage>
          <MedlinePgn>1147-1161</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1007/s40123-022-00493-z</ELocationID>
        <Abstract>
          <AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">The aim of this nationwide, prospective post-marketing surveillance was to assess the safety and effectiveness of up to 52 weeks of adalimumab treatment in patients with noninfectious intermediate, posterior, or panuveitis in Japanese clinical practice.</AbstractText>
          <AbstractText Label="METHODS" NlmCategory="METHODS">This post-marketing surveillance was conducted at 60 medical facilities in Japan from October 2016 to June 2020. Patients with noninfectious intermediate, posterior, or panuveitis who were administered adalimumab (Humira<sup>®</sup>, AbbVie Inc.) for the first time were eligible. Subcutaneous adalimumab was initially administered at 80 mg, followed by 40 mg 1 week later, then 40 mg every 2 weeks. Safety measures included the incidence of adverse events (AEs) and adverse drug reactions (ADRs; primary endpoint). Effectiveness measures included visual acuity, anterior chamber cell grade, vitreous haze, macular edema, foveal retinal thickness, uveitis recurrence rate, and oral corticosteroid dose. Health-related quality of life was evaluated using the 25-item National Eye Institute Visual Function Questionnaire (VFQ-25).</AbstractText>
          <AbstractText Label="RESULTS" NlmCategory="RESULTS">During 52 weeks of surveillance, AEs and ADRs occurred in 70 (27.9%) and 47 (18.7%) of 251 patients, respectively. The most common ADR was infection (21/251 patients; 8.4%), including serious infections in eight (3.2%) patients. ADRs were more frequent in patients ≥ 65 years of age, those with concurrent diseases, and those with past medical history. Four patients developed tuberculosis. The uveitis recurrence rate was 24.8% (61/246 patients). All effectiveness measures tended to improve from baseline to week 52, and mean corticosteroid doses decreased. Clinically meaningful changes were observed for most VFQ-25 subscales.</AbstractText>
          <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The safety profile of adalimumab was generally consistent with previous reports, and no new safety concerns were identified.</AbstractText>
          <AbstractText Label="TRIAL REGISTRATION" NlmCategory="BACKGROUND">ClinicalTrials.gov: NCT02916017.</AbstractText>
          <CopyrightInformation>© 2022. The Author(s).</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Namba</LastName>
            <ForeName>Kenichi</ForeName>
            <Initials>K</Initials>
            <Identifier Source="ORCID">0000-0002-5016-851X</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Ophthalmology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Kita 15, Nishi 7, Kita-ku, Sapporo, Hokkaido, 060-8638, Japan. knamba@med.hokudai.ac.jp.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kaburaki</LastName>
            <ForeName>Toshikatsu</ForeName>
            <Initials>T</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Ophthalmology, University of Tokyo School of Medicine, Tokyo, Japan.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Ophthalmology, Jichi Medical University Saitama Medical Center, Saitama, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Tsuruga</LastName>
            <ForeName>Hidekazu</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>AbbVie GK, Tokyo, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ogawa</LastName>
            <ForeName>Yohei</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>AbbVie GK, Tokyo, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Iwashita</LastName>
            <ForeName>Eri</ForeName>
            <Initials>E</Initials>
            <AffiliationInfo>
              <Affiliation>AbbVie GK, Tokyo, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Goto</LastName>
            <ForeName>Hiroshi</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Ophthalmology, Tokyo Medical University, Tokyo, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <DataBankList CompleteYN="Y">
          <DataBank>
            <DataBankName>ClinicalTrials.gov</DataBankName>
            <AccessionNumberList>
              <AccessionNumber>NCT02916017</AccessionNumber>
            </AccessionNumberList>
          </DataBank>
        </DataBankList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>03</Month>
          <Day>19</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Ophthalmol Ther</MedlineTA>
        <NlmUniqueID>101634502</NlmUniqueID>
      </MedlineJournalInfo>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Adalimumab</Keyword>
        <Keyword MajorTopicYN="N">Behçet’s Disease</Keyword>
        <Keyword MajorTopicYN="N">Sarcoidosis</Keyword>
        <Keyword MajorTopicYN="N">Uveitis</Keyword>
        <Keyword MajorTopicYN="N">Vogt-Koyanagi-Harada Disease</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>11</Month>
          <Day>16</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>24</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>20</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>20</Day>
          <Hour>6</Hour>
          <Minute>1</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>19</Day>
          <Hour>17</Hour>
          <Minute>8</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35305254</ArticleId>
        <ArticleId IdType="pmc">PMC9114192</ArticleId>
        <ArticleId IdType="doi">10.1007/s40123-022-00493-z</ArticleId>
        <ArticleId IdType="pii">10.1007/s40123-022-00493-z</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Sonoda KH, Hasegawa E, Namba K, et al.  Epidemiology of uveitis in Japan: a 2016 retrospective nationwide survey. Jpn J Ophthalmol. 2021;65(2):184–190. doi: 10.1007/s10384-020-00809-1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s10384-020-00809-1</ArticleId>
            <ArticleId IdType="pubmed">33694024</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lee RW, Dick AD. Current concepts and future directions in the pathogenesis and treatment of non-infectious intraocular inflammation. Eye (Lond) 2012;26(1):17–28. doi: 10.1038/eye.2011.255.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/eye.2011.255</ArticleId>
            <ArticleId IdType="pmc">PMC3259588</ArticleId>
            <ArticleId IdType="pubmed">21960067</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rossi DC, Ribi C, Guex-Crosier Y. Treatment of chronic non-infectious uveitis and scleritis. Swiss Med Wkly. 2019;149:w20025.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30852832</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Castiblanco C, Foster CS. Review of systemic immunosuppression for autoimmune uveitis. Ophthalmol Ther. 2014;3(1–2):17–36. doi: 10.1007/s40123-014-0023-x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s40123-014-0023-x</ArticleId>
            <ArticleId IdType="pmc">PMC4254861</ArticleId>
            <ArticleId IdType="pubmed">25134495</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jabs DA, Rosenbaum JT, Foster CS, et al.  Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel. Am J Ophthalmol. 2000;130(4):492–513. doi: 10.1016/S0002-9394(00)00659-0.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0002-9394(00)00659-0</ArticleId>
            <ArticleId IdType="pubmed">11024423</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Valenzuela RA, Flores I, Urrutia B, et al.  New pharmacological strategies for the treatment of non-infectious uveitis. A minireview. Front Pharmacol. 2020;11:655. doi: 10.3389/fphar.2020.00655.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fphar.2020.00655</ArticleId>
            <ArticleId IdType="pmc">PMC7250389</ArticleId>
            <ArticleId IdType="pubmed">32508634</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ohno S, Umebayashi I, Matsukawa M, Goto T, Yano T. Safety and efficacy of infliximab in the treatment of refractory uveoretinitis in Behçet's disease: a large-scale, long-term postmarketing surveillance in Japan. Arthritis Res Ther. 2019;21(1):2. doi: 10.1186/s13075-018-1793-7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s13075-018-1793-7</ArticleId>
            <ArticleId IdType="pmc">PMC6321670</ArticleId>
            <ArticleId IdType="pubmed">30611312</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen JL, Lobo-Chan A-M, Chan RVP, Bhat P.  Tumor necrosis factor-alpha inhibitory therapy for non-infectious autoimmune uveitis. In: Rodriguez-Garcia A, Foster CS, editors. Advances in the diagnosis and management of uveitis. London: IntechOpen; 2019. pp. 115–133.</Citation>
        </Reference>
        <Reference>
          <Citation>Jaffe GJ, Dick AD, Brézin AP, et al.  Adalimumab in patients with active noninfectious uveitis. N Engl J Med. 2016;375(10):932–943. doi: 10.1056/NEJMoa1509852.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa1509852</ArticleId>
            <ArticleId IdType="pubmed">27602665</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nguyen QD, Merrill PT, Jaffe GJ, et al.  Adalimumab for prevention of uveitic flare in patients with inactive non-infectious uveitis controlled by corticosteroids (VISUAL II): a multicentre, double-masked, randomised, placebo-controlled phase 3 trial. Lancet. 2016;388(10050):1183–1192. doi: 10.1016/S0140-6736(16)31339-3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0140-6736(16)31339-3</ArticleId>
            <ArticleId IdType="pubmed">27542302</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cantini F, Niccoli L, Goletti D. Adalimumab, etanercept, infliximab, and the risk of tuberculosis: data from clinical trials, national registries, and postmarketing surveillance. J Rheumatol Suppl. 2014;91:47–55. doi: 10.3899/jrheum.140102.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3899/jrheum.140102</ArticleId>
            <ArticleId IdType="pubmed">24789000</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Minozzi S, Bonovas S, Lytras T, et al.  Risk of infections using anti-TNF agents in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: a systematic review and meta-analysis. Expert Opin Drug Saf. 2016;15(sup1):11–34. doi: 10.1080/14740338.2016.1240783.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/14740338.2016.1240783</ArticleId>
            <ArticleId IdType="pubmed">27924643</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Suhler EB, Jaffe GJ, Fortin E, et al.  Long-term safety and efficacy of adalimumab in patients with noninfectious intermediate uveitis, posterior uveitis, or panuveitis. Ophthalmology. 2021;128:899–909. doi: 10.1016/j.ophtha.2020.10.036.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ophtha.2020.10.036</ArticleId>
            <ArticleId IdType="pubmed">33157077</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bitossi A, Bettiol A, Silvestri E, et al.  Adalimumab accounts for long-term control of noninfectious uveitis also in the absence of concomitant DMARD treatment: a multicenter retrospective study. Mediat Inflamm. 2019;2019:1623847. doi: 10.1155/2019/1623847.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1155/2019/1623847</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fabiani C, Sota J, Vitale A, et al.  Cumulative retention rate of adalimumab in patients with Behçet's disease-related uveitis: a four-year follow-up study. Br J Ophthalmol. 2018;102(5):637–641. doi: 10.1136/bjophthalmol-2017-310733.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/bjophthalmol-2017-310733</ArticleId>
            <ArticleId IdType="pubmed">28844047</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fabiani C, Vitale A, Rigante D, et al.  Comparative efficacy between adalimumab and infliximab in the treatment of non-infectious intermediate uveitis, posterior uveitis, and panuveitis: a retrospective observational study of 107 patients. Clin Rheumatol. 2019;38(2):407–415. doi: 10.1007/s10067-018-4228-6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s10067-018-4228-6</ArticleId>
            <ArticleId IdType="pubmed">30099655</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hiyama T, Harada Y, Kiuchi Y. Efficacy and safety of adalimumab therapy for the treatment of non-infectious uveitis: efficacy comparison among uveitis aetiologies. Ocul Immunol Inflamm. 2021 doi: 10.1080/09273948.2020.1857791.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/09273948.2020.1857791</ArticleId>
            <ArticleId IdType="pubmed">33560160</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kunimi K, Usui Y, Asakage M, et al.  Anti-TNF-α therapy for refractory uveitis associated with Behçet's syndrome and sarcoidosis: a single center study of 131 patients. Ocul Immunol Inflamm. 2020 doi: 10.1080/09273948.2020.1791346.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/09273948.2020.1791346</ArticleId>
            <ArticleId IdType="pubmed">32815752</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lee JT, Yates WB, Rogers S, Wakefield D, McCluskey P, Lim LL. Adalimumab for the treatment of refractory active and inactive non-infectious uveitis. Br J Ophthalmol. 2018;102(12):1672–1678. doi: 10.1136/bjophthalmol-2017-311234.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/bjophthalmol-2017-311234</ArticleId>
            <ArticleId IdType="pubmed">29459430</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sota J, Gentileschi S, Vitale A, et al.  Effectiveness of SB5, an adalimumab biosimilar, in patients with noninfectious uveitis: a real-life monocentric experience. Asia Pac J Ophthalmol (Phila) 2021;10(4):360–365. doi: 10.1097/APO.0000000000000380.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/APO.0000000000000380</ArticleId>
            <ArticleId IdType="pubmed">33756492</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tang-Lee-Say TL, Yang V, Fingret JM, et al.  Adalimumab in patients with vision-threatening uveitis: real-world clinical experience. BMJ Open Ophthalmol. 2021;6(1):e000819. doi: 10.1136/bmjophth-2021-000819.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/bmjophth-2021-000819</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>World Health Organization. Global Tuberculosis Report. 2020. https://apps.who.int/iris/bitstream/handle/10665/336069/9789240013131-eng.pdf. Accessed 8 Jul 2021.</Citation>
        </Reference>
        <Reference>
          <Citation>Japanese Ocular Inflammation Society. TNF Inhibitor Use Guidelines and Safety Measures Manual for Non-Infectious Uveitis (2nd Edition) [in Japanese]. 2019. http://jois.umin.jp/TNF.pdf. Accessed 8 Jul 2021.</Citation>
        </Reference>
        <Reference>
          <Citation>Jabs DA, Nussenblatt RB, Rosenbaum JT, Standardization of Uveitis Nomenclature (SUN) Working Group  Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop. Am J Ophthalmol. 2005;140(3):509–516. doi: 10.1016/j.ajo.2005.03.057.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ajo.2005.03.057</ArticleId>
            <ArticleId IdType="pmc">PMC8935739</ArticleId>
            <ArticleId IdType="pubmed">16196117</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nussenblatt RB, Palestine AG, Chan CC, Roberge F. Standardization of vitreal inflammatory activity in intermediate and posterior uveitis. Ophthalmology. 1985;92(4):467–471. doi: 10.1016/S0161-6420(85)34001-0.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0161-6420(85)34001-0</ArticleId>
            <ArticleId IdType="pubmed">4000641</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Trusko B, Thorne J, Jabs D, et al.  The Standardization of Uveitis Nomenclature (SUN) Project. Development of a clinical evidence base utilizing informatics tools and techniques. Methods Inf Med. 2013;52(3):259–265. doi: 10.3414/ME12-01-0063.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3414/ME12-01-0063</ArticleId>
            <ArticleId IdType="pmc">PMC8728398</ArticleId>
            <ArticleId IdType="pubmed">23392263</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mangione CM, Lee PP, Gutierrez PR, et al.  Development of the 25-item National Eye Institute Visual Function Questionnaire. Arch Ophthalmol. 2001;119(7):1050–1058. doi: 10.1001/archopht.119.7.1050.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/archopht.119.7.1050</ArticleId>
            <ArticleId IdType="pubmed">11448327</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Suñer IJ, Kokame GT, Yu E, Ward J, Dolan C, Bressler NM. Responsiveness of NEI VFQ-25 to changes in visual acuity in neovascular AMD: validation studies from two phase 3 clinical trials. Invest Ophthalmol Vis Sci. 2009;50(8):3629–3635. doi: 10.1167/iovs.08-3225.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1167/iovs.08-3225</ArticleId>
            <ArticleId IdType="pubmed">19255158</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Goto H, Zako M, Namba K, et al.  Adalimumab in active and inactive, non-infectious uveitis: global results from the VISUAL I and VISUAL II trials. Ocul Immunol Inflamm. 2019;27(1):40–50. doi: 10.1080/09273948.2018.1491605.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/09273948.2018.1491605</ArticleId>
            <ArticleId IdType="pubmed">30015528</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Burmester GR, Panaccione R, Gordon KB, McIlraith MJ, Lacerda APM. Adalimumab: long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn's disease. Ann Rheum Dis. 2013;72(4):517–524. doi: 10.1136/annrheumdis-2011-201244.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/annrheumdis-2011-201244</ArticleId>
            <ArticleId IdType="pmc">PMC3595151</ArticleId>
            <ArticleId IdType="pubmed">22562972</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Koike T, Harigai M, Ishiguro N, et al.  Safety and effectiveness of adalimumab in Japanese rheumatoid arthritis patients: postmarketing surveillance report of 7740 patients. Mod Rheumatol. 2014;24(3):390–398. doi: 10.3109/14397595.2013.843760.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3109/14397595.2013.843760</ArticleId>
            <ArticleId IdType="pubmed">24252049</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Koike T, Harigai M, Ishiguro N, et al.  Safety and effectiveness of adalimumab in Japanese rheumatoid arthritis patients: postmarketing surveillance report of the first 3,000 patients. Mod Rheumatol. 2012;22(4):498–508. doi: 10.3109/s10165-011-0541-5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3109/s10165-011-0541-5</ArticleId>
            <ArticleId IdType="pubmed">21993918</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ogata H, Watanabe M, Matsui T, et al.  Safety of adalimumab and predictors of adverse events in 1693 Japanese patients with Crohn's disease. J Crohns Colitis. 2016;10(9):1033–1041. doi: 10.1093/ecco-jcc/jjw060.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/ecco-jcc/jjw060</ArticleId>
            <ArticleId IdType="pmc">PMC5007524</ArticleId>
            <ArticleId IdType="pubmed">26961546</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Suzuki Y, Hagiwara T, Kobayashi M, Morita K, Shimamoto T, Hibi T. Is adalimumab safe and effective in patients with intestinal Behcet's disease in real-world practice? Intest Res. 2021;19(3):301–312. doi: 10.5217/ir.2020.00013.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.5217/ir.2020.00013</ArticleId>
            <ArticleId IdType="pmc">PMC8322033</ArticleId>
            <ArticleId IdType="pubmed">32814420</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Takeuchi T, Tatsuki Y, Nogami Y, et al.  Postmarketing surveillance of the safety profile of infliximab in 5000 Japanese patients with rheumatoid arthritis. Ann Rheum Dis. 2008;67(2):189–194. doi: 10.1136/ard.2007.072967.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/ard.2007.072967</ArticleId>
            <ArticleId IdType="pubmed">17644554</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Naik RK, Rentz AM, Foster CS, et al.  Normative comparison of patient-reported outcomes in patients with noninfectious uveitis. JAMA Ophthalmol. 2013;131(2):219–225. doi: 10.1001/2013.jamaophthalmol.102.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/2013.jamaophthalmol.102</ArticleId>
            <ArticleId IdType="pubmed">23411886</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sheppard J, Joshi A, Betts KA, et al.  Effect of adalimumab on visual functioning in patients with noninfectious intermediate uveitis, posterior uveitis, and panuveitis in the VISUAL-1 and VISUAL-2 trials. JAMA Ophthalmol. 2017;135(6):511–518. doi: 10.1001/jamaophthalmol.2017.0603.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/jamaophthalmol.2017.0603</ArticleId>
            <ArticleId IdType="pmc">PMC5847080</ArticleId>
            <ArticleId IdType="pubmed">28426849</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Duru N, van der Goes MC, Jacobs JWG, et al.  EULAR evidence-based and consensus-based recommendations on the management of medium to high-dose glucocorticoid therapy in rheumatic diseases. Ann Rheum Dis. 2013;72(12):1905–1913. doi: 10.1136/annrheumdis-2013-203249.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/annrheumdis-2013-203249</ArticleId>
            <ArticleId IdType="pubmed">23873876</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Manson SC, Brown RE, Cerulli A, Vidaurre CF. The cumulative burden of oral corticosteroid side effects and the economic implications of steroid use. Respir Med. 2009;103(7):975–994. doi: 10.1016/j.rmed.2009.01.003.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.rmed.2009.01.003</ArticleId>
            <ArticleId IdType="pubmed">19372037</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Strehl C, Bijlsma JWJ, de Wit M, et al.  Defining conditions where long-term glucocorticoid treatment has an acceptably low level of harm to facilitate implementation of existing recommendations: viewpoints from an EULAR task force. Ann Rheum Dis. 2016;75(6):952–957. doi: 10.1136/annrheumdis-2015-208916.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/annrheumdis-2015-208916</ArticleId>
            <ArticleId IdType="pubmed">26933146</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM">
      <PMID Version="1">35305254</PMID>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>20</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Print">2193-8245</ISSN>
          <JournalIssue CitedMedium="Print">
            <Volume>11</Volume>
            <Issue>3</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Jun</Month>
            </PubDate>
          </JournalIssue>
          <Title>Ophthalmology and therapy</Title>
          <ISOAbbreviation>Ophthalmol Ther</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Long-Term Safety and Effectiveness of Adalimumab in Japanese Patients with Noninfectious Intermediate, Posterior, or Panuveitis: Post-Marketing Surveillance of 251 Patients.</ArticleTitle>
        <Pagination>
          <StartPage>1147</StartPage>
          <EndPage>1161</EndPage>
          <MedlinePgn>1147-1161</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1007/s40123-022-00493-z</ELocationID>
        <Abstract>
          <AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">The aim of this nationwide, prospective post-marketing surveillance was to assess the safety and effectiveness of up to 52 weeks of adalimumab treatment in patients with noninfectious intermediate, posterior, or panuveitis in Japanese clinical practice.</AbstractText>
          <AbstractText Label="METHODS" NlmCategory="METHODS">This post-marketing surveillance was conducted at 60 medical facilities in Japan from October 2016 to June 2020. Patients with noninfectious intermediate, posterior, or panuveitis who were administered adalimumab (Humira<sup>®</sup>, AbbVie Inc.) for the first time were eligible. Subcutaneous adalimumab was initially administered at 80 mg, followed by 40 mg 1 week later, then 40 mg every 2 weeks. Safety measures included the incidence of adverse events (AEs) and adverse drug reactions (ADRs; primary endpoint). Effectiveness measures included visual acuity, anterior chamber cell grade, vitreous haze, macular edema, foveal retinal thickness, uveitis recurrence rate, and oral corticosteroid dose. Health-related quality of life was evaluated using the 25-item National Eye Institute Visual Function Questionnaire (VFQ-25).</AbstractText>
          <AbstractText Label="RESULTS" NlmCategory="RESULTS">During 52 weeks of surveillance, AEs and ADRs occurred in 70 (27.9%) and 47 (18.7%) of 251 patients, respectively. The most common ADR was infection (21/251 patients; 8.4%), including serious infections in eight (3.2%) patients. ADRs were more frequent in patients ≥ 65 years of age, those with concurrent diseases, and those with past medical history. Four patients developed tuberculosis. The uveitis recurrence rate was 24.8% (61/246 patients). All effectiveness measures tended to improve from baseline to week 52, and mean corticosteroid doses decreased. Clinically meaningful changes were observed for most VFQ-25 subscales.</AbstractText>
          <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The safety profile of adalimumab was generally consistent with previous reports, and no new safety concerns were identified.</AbstractText>
          <AbstractText Label="TRIAL REGISTRATION" NlmCategory="BACKGROUND">ClinicalTrials.gov: NCT02916017.</AbstractText>
          <CopyrightInformation>© 2022. The Author(s).</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Namba</LastName>
            <ForeName>Kenichi</ForeName>
            <Initials>K</Initials>
            <Identifier Source="ORCID">0000-0002-5016-851X</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Ophthalmology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Kita 15, Nishi 7, Kita-ku, Sapporo, Hokkaido, 060-8638, Japan. knamba@med.hokudai.ac.jp.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kaburaki</LastName>
            <ForeName>Toshikatsu</ForeName>
            <Initials>T</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Ophthalmology, University of Tokyo School of Medicine, Tokyo, Japan.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Ophthalmology, Jichi Medical University Saitama Medical Center, Saitama, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Tsuruga</LastName>
            <ForeName>Hidekazu</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>AbbVie GK, Tokyo, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ogawa</LastName>
            <ForeName>Yohei</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>AbbVie GK, Tokyo, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Iwashita</LastName>
            <ForeName>Eri</ForeName>
            <Initials>E</Initials>
            <AffiliationInfo>
              <Affiliation>AbbVie GK, Tokyo, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Goto</LastName>
            <ForeName>Hiroshi</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Ophthalmology, Tokyo Medical University, Tokyo, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <DataBankList CompleteYN="Y">
          <DataBank>
            <DataBankName>ClinicalTrials.gov</DataBankName>
            <AccessionNumberList>
              <AccessionNumber>NCT02916017</AccessionNumber>
            </AccessionNumberList>
          </DataBank>
        </DataBankList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>03</Month>
          <Day>19</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Ophthalmol Ther</MedlineTA>
        <NlmUniqueID>101634502</NlmUniqueID>
      </MedlineJournalInfo>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Adalimumab</Keyword>
        <Keyword MajorTopicYN="N">Behçet’s Disease</Keyword>
        <Keyword MajorTopicYN="N">Sarcoidosis</Keyword>
        <Keyword MajorTopicYN="N">Uveitis</Keyword>
        <Keyword MajorTopicYN="N">Vogt-Koyanagi-Harada Disease</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>11</Month>
          <Day>16</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>24</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>20</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>20</Day>
          <Hour>6</Hour>
          <Minute>1</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>19</Day>
          <Hour>17</Hour>
          <Minute>8</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35305254</ArticleId>
        <ArticleId IdType="pmc">PMC9114192</ArticleId>
        <ArticleId IdType="doi">10.1007/s40123-022-00493-z</ArticleId>
        <ArticleId IdType="pii">10.1007/s40123-022-00493-z</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Sonoda KH, Hasegawa E, Namba K, et al.  Epidemiology of uveitis in Japan: a 2016 retrospective nationwide survey. Jpn J Ophthalmol. 2021;65(2):184–190. doi: 10.1007/s10384-020-00809-1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s10384-020-00809-1</ArticleId>
            <ArticleId IdType="pubmed">33694024</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lee RW, Dick AD. Current concepts and future directions in the pathogenesis and treatment of non-infectious intraocular inflammation. Eye (Lond) 2012;26(1):17–28. doi: 10.1038/eye.2011.255.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/eye.2011.255</ArticleId>
            <ArticleId IdType="pmc">PMC3259588</ArticleId>
            <ArticleId IdType="pubmed">21960067</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rossi DC, Ribi C, Guex-Crosier Y. Treatment of chronic non-infectious uveitis and scleritis. Swiss Med Wkly. 2019;149:w20025.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30852832</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Castiblanco C, Foster CS. Review of systemic immunosuppression for autoimmune uveitis. Ophthalmol Ther. 2014;3(1–2):17–36. doi: 10.1007/s40123-014-0023-x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s40123-014-0023-x</ArticleId>
            <ArticleId IdType="pmc">PMC4254861</ArticleId>
            <ArticleId IdType="pubmed">25134495</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jabs DA, Rosenbaum JT, Foster CS, et al.  Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel. Am J Ophthalmol. 2000;130(4):492–513. doi: 10.1016/S0002-9394(00)00659-0.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0002-9394(00)00659-0</ArticleId>
            <ArticleId IdType="pubmed">11024423</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Valenzuela RA, Flores I, Urrutia B, et al.  New pharmacological strategies for the treatment of non-infectious uveitis. A minireview. Front Pharmacol. 2020;11:655. doi: 10.3389/fphar.2020.00655.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fphar.2020.00655</ArticleId>
            <ArticleId IdType="pmc">PMC7250389</ArticleId>
            <ArticleId IdType="pubmed">32508634</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ohno S, Umebayashi I, Matsukawa M, Goto T, Yano T. Safety and efficacy of infliximab in the treatment of refractory uveoretinitis in Behçet's disease: a large-scale, long-term postmarketing surveillance in Japan. Arthritis Res Ther. 2019;21(1):2. doi: 10.1186/s13075-018-1793-7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s13075-018-1793-7</ArticleId>
            <ArticleId IdType="pmc">PMC6321670</ArticleId>
            <ArticleId IdType="pubmed">30611312</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen JL, Lobo-Chan A-M, Chan RVP, Bhat P.  Tumor necrosis factor-alpha inhibitory therapy for non-infectious autoimmune uveitis. In: Rodriguez-Garcia A, Foster CS, editors. Advances in the diagnosis and management of uveitis. London: IntechOpen; 2019. pp. 115–133.</Citation>
        </Reference>
        <Reference>
          <Citation>Jaffe GJ, Dick AD, Brézin AP, et al.  Adalimumab in patients with active noninfectious uveitis. N Engl J Med. 2016;375(10):932–943. doi: 10.1056/NEJMoa1509852.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa1509852</ArticleId>
            <ArticleId IdType="pubmed">27602665</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nguyen QD, Merrill PT, Jaffe GJ, et al.  Adalimumab for prevention of uveitic flare in patients with inactive non-infectious uveitis controlled by corticosteroids (VISUAL II): a multicentre, double-masked, randomised, placebo-controlled phase 3 trial. Lancet. 2016;388(10050):1183–1192. doi: 10.1016/S0140-6736(16)31339-3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0140-6736(16)31339-3</ArticleId>
            <ArticleId IdType="pubmed">27542302</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cantini F, Niccoli L, Goletti D. Adalimumab, etanercept, infliximab, and the risk of tuberculosis: data from clinical trials, national registries, and postmarketing surveillance. J Rheumatol Suppl. 2014;91:47–55. doi: 10.3899/jrheum.140102.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3899/jrheum.140102</ArticleId>
            <ArticleId IdType="pubmed">24789000</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Minozzi S, Bonovas S, Lytras T, et al.  Risk of infections using anti-TNF agents in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: a systematic review and meta-analysis. Expert Opin Drug Saf. 2016;15(sup1):11–34. doi: 10.1080/14740338.2016.1240783.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/14740338.2016.1240783</ArticleId>
            <ArticleId IdType="pubmed">27924643</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Suhler EB, Jaffe GJ, Fortin E, et al.  Long-term safety and efficacy of adalimumab in patients with noninfectious intermediate uveitis, posterior uveitis, or panuveitis. Ophthalmology. 2021;128:899–909. doi: 10.1016/j.ophtha.2020.10.036.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ophtha.2020.10.036</ArticleId>
            <ArticleId IdType="pubmed">33157077</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bitossi A, Bettiol A, Silvestri E, et al.  Adalimumab accounts for long-term control of noninfectious uveitis also in the absence of concomitant DMARD treatment: a multicenter retrospective study. Mediat Inflamm. 2019;2019:1623847. doi: 10.1155/2019/1623847.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1155/2019/1623847</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fabiani C, Sota J, Vitale A, et al.  Cumulative retention rate of adalimumab in patients with Behçet's disease-related uveitis: a four-year follow-up study. Br J Ophthalmol. 2018;102(5):637–641. doi: 10.1136/bjophthalmol-2017-310733.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/bjophthalmol-2017-310733</ArticleId>
            <ArticleId IdType="pubmed">28844047</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fabiani C, Vitale A, Rigante D, et al.  Comparative efficacy between adalimumab and infliximab in the treatment of non-infectious intermediate uveitis, posterior uveitis, and panuveitis: a retrospective observational study of 107 patients. Clin Rheumatol. 2019;38(2):407–415. doi: 10.1007/s10067-018-4228-6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s10067-018-4228-6</ArticleId>
            <ArticleId IdType="pubmed">30099655</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hiyama T, Harada Y, Kiuchi Y. Efficacy and safety of adalimumab therapy for the treatment of non-infectious uveitis: efficacy comparison among uveitis aetiologies. Ocul Immunol Inflamm. 2021 doi: 10.1080/09273948.2020.1857791.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/09273948.2020.1857791</ArticleId>
            <ArticleId IdType="pubmed">33560160</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kunimi K, Usui Y, Asakage M, et al.  Anti-TNF-α therapy for refractory uveitis associated with Behçet's syndrome and sarcoidosis: a single center study of 131 patients. Ocul Immunol Inflamm. 2020 doi: 10.1080/09273948.2020.1791346.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/09273948.2020.1791346</ArticleId>
            <ArticleId IdType="pubmed">32815752</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lee JT, Yates WB, Rogers S, Wakefield D, McCluskey P, Lim LL. Adalimumab for the treatment of refractory active and inactive non-infectious uveitis. Br J Ophthalmol. 2018;102(12):1672–1678. doi: 10.1136/bjophthalmol-2017-311234.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/bjophthalmol-2017-311234</ArticleId>
            <ArticleId IdType="pubmed">29459430</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sota J, Gentileschi S, Vitale A, et al.  Effectiveness of SB5, an adalimumab biosimilar, in patients with noninfectious uveitis: a real-life monocentric experience. Asia Pac J Ophthalmol (Phila) 2021;10(4):360–365. doi: 10.1097/APO.0000000000000380.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/APO.0000000000000380</ArticleId>
            <ArticleId IdType="pubmed">33756492</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tang-Lee-Say TL, Yang V, Fingret JM, et al.  Adalimumab in patients with vision-threatening uveitis: real-world clinical experience. BMJ Open Ophthalmol. 2021;6(1):e000819. doi: 10.1136/bmjophth-2021-000819.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/bmjophth-2021-000819</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>World Health Organization. Global Tuberculosis Report. 2020. https://apps.who.int/iris/bitstream/handle/10665/336069/9789240013131-eng.pdf. Accessed 8 Jul 2021.</Citation>
        </Reference>
        <Reference>
          <Citation>Japanese Ocular Inflammation Society. TNF Inhibitor Use Guidelines and Safety Measures Manual for Non-Infectious Uveitis (2nd Edition) [in Japanese]. 2019. http://jois.umin.jp/TNF.pdf. Accessed 8 Jul 2021.</Citation>
        </Reference>
        <Reference>
          <Citation>Jabs DA, Nussenblatt RB, Rosenbaum JT, Standardization of Uveitis Nomenclature (SUN) Working Group  Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop. Am J Ophthalmol. 2005;140(3):509–516. doi: 10.1016/j.ajo.2005.03.057.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ajo.2005.03.057</ArticleId>
            <ArticleId IdType="pmc">PMC8935739</ArticleId>
            <ArticleId IdType="pubmed">16196117</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nussenblatt RB, Palestine AG, Chan CC, Roberge F. Standardization of vitreal inflammatory activity in intermediate and posterior uveitis. Ophthalmology. 1985;92(4):467–471. doi: 10.1016/S0161-6420(85)34001-0.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0161-6420(85)34001-0</ArticleId>
            <ArticleId IdType="pubmed">4000641</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Trusko B, Thorne J, Jabs D, et al.  The Standardization of Uveitis Nomenclature (SUN) Project. Development of a clinical evidence base utilizing informatics tools and techniques. Methods Inf Med. 2013;52(3):259–265. doi: 10.3414/ME12-01-0063.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3414/ME12-01-0063</ArticleId>
            <ArticleId IdType="pmc">PMC8728398</ArticleId>
            <ArticleId IdType="pubmed">23392263</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mangione CM, Lee PP, Gutierrez PR, et al.  Development of the 25-item National Eye Institute Visual Function Questionnaire. Arch Ophthalmol. 2001;119(7):1050–1058. doi: 10.1001/archopht.119.7.1050.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/archopht.119.7.1050</ArticleId>
            <ArticleId IdType="pubmed">11448327</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Suñer IJ, Kokame GT, Yu E, Ward J, Dolan C, Bressler NM. Responsiveness of NEI VFQ-25 to changes in visual acuity in neovascular AMD: validation studies from two phase 3 clinical trials. Invest Ophthalmol Vis Sci. 2009;50(8):3629–3635. doi: 10.1167/iovs.08-3225.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1167/iovs.08-3225</ArticleId>
            <ArticleId IdType="pubmed">19255158</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Goto H, Zako M, Namba K, et al.  Adalimumab in active and inactive, non-infectious uveitis: global results from the VISUAL I and VISUAL II trials. Ocul Immunol Inflamm. 2019;27(1):40–50. doi: 10.1080/09273948.2018.1491605.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/09273948.2018.1491605</ArticleId>
            <ArticleId IdType="pubmed">30015528</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Burmester GR, Panaccione R, Gordon KB, McIlraith MJ, Lacerda APM. Adalimumab: long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn's disease. Ann Rheum Dis. 2013;72(4):517–524. doi: 10.1136/annrheumdis-2011-201244.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/annrheumdis-2011-201244</ArticleId>
            <ArticleId IdType="pmc">PMC3595151</ArticleId>
            <ArticleId IdType="pubmed">22562972</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Koike T, Harigai M, Ishiguro N, et al.  Safety and effectiveness of adalimumab in Japanese rheumatoid arthritis patients: postmarketing surveillance report of 7740 patients. Mod Rheumatol. 2014;24(3):390–398. doi: 10.3109/14397595.2013.843760.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3109/14397595.2013.843760</ArticleId>
            <ArticleId IdType="pubmed">24252049</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Koike T, Harigai M, Ishiguro N, et al.  Safety and effectiveness of adalimumab in Japanese rheumatoid arthritis patients: postmarketing surveillance report of the first 3,000 patients. Mod Rheumatol. 2012;22(4):498–508. doi: 10.3109/s10165-011-0541-5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3109/s10165-011-0541-5</ArticleId>
            <ArticleId IdType="pubmed">21993918</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ogata H, Watanabe M, Matsui T, et al.  Safety of adalimumab and predictors of adverse events in 1693 Japanese patients with Crohn's disease. J Crohns Colitis. 2016;10(9):1033–1041. doi: 10.1093/ecco-jcc/jjw060.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/ecco-jcc/jjw060</ArticleId>
            <ArticleId IdType="pmc">PMC5007524</ArticleId>
            <ArticleId IdType="pubmed">26961546</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Suzuki Y, Hagiwara T, Kobayashi M, Morita K, Shimamoto T, Hibi T. Is adalimumab safe and effective in patients with intestinal Behcet's disease in real-world practice? Intest Res. 2021;19(3):301–312. doi: 10.5217/ir.2020.00013.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.5217/ir.2020.00013</ArticleId>
            <ArticleId IdType="pmc">PMC8322033</ArticleId>
            <ArticleId IdType="pubmed">32814420</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Takeuchi T, Tatsuki Y, Nogami Y, et al.  Postmarketing surveillance of the safety profile of infliximab in 5000 Japanese patients with rheumatoid arthritis. Ann Rheum Dis. 2008;67(2):189–194. doi: 10.1136/ard.2007.072967.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/ard.2007.072967</ArticleId>
            <ArticleId IdType="pubmed">17644554</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Naik RK, Rentz AM, Foster CS, et al.  Normative comparison of patient-reported outcomes in patients with noninfectious uveitis. JAMA Ophthalmol. 2013;131(2):219–225. doi: 10.1001/2013.jamaophthalmol.102.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/2013.jamaophthalmol.102</ArticleId>
            <ArticleId IdType="pubmed">23411886</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sheppard J, Joshi A, Betts KA, et al.  Effect of adalimumab on visual functioning in patients with noninfectious intermediate uveitis, posterior uveitis, and panuveitis in the VISUAL-1 and VISUAL-2 trials. JAMA Ophthalmol. 2017;135(6):511–518. doi: 10.1001/jamaophthalmol.2017.0603.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/jamaophthalmol.2017.0603</ArticleId>
            <ArticleId IdType="pmc">PMC5847080</ArticleId>
            <ArticleId IdType="pubmed">28426849</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Duru N, van der Goes MC, Jacobs JWG, et al.  EULAR evidence-based and consensus-based recommendations on the management of medium to high-dose glucocorticoid therapy in rheumatic diseases. Ann Rheum Dis. 2013;72(12):1905–1913. doi: 10.1136/annrheumdis-2013-203249.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/annrheumdis-2013-203249</ArticleId>
            <ArticleId IdType="pubmed">23873876</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Manson SC, Brown RE, Cerulli A, Vidaurre CF. The cumulative burden of oral corticosteroid side effects and the economic implications of steroid use. Respir Med. 2009;103(7):975–994. doi: 10.1016/j.rmed.2009.01.003.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.rmed.2009.01.003</ArticleId>
            <ArticleId IdType="pubmed">19372037</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Strehl C, Bijlsma JWJ, de Wit M, et al.  Defining conditions where long-term glucocorticoid treatment has an acceptably low level of harm to facilitate implementation of existing recommendations: viewpoints from an EULAR task force. Ann Rheum Dis. 2016;75(6):952–957. doi: 10.1136/annrheumdis-2015-208916.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/annrheumdis-2015-208916</ArticleId>
            <ArticleId IdType="pubmed">26933146</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
